Ratings by Piper Sandler (Biren Amin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/26/2026 | Connect Biopharma Holdings Ltd | CNTB | New Coverage | Overweight (N/A) |
2.12 (2.46) |
16.04% | Details | |
| 5/18/2026 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2026 | Solid Biosciences | SLDB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2026 | LENZ Therapeutics Inc | LENZ | Downgrade | Neutral (Overweight) |
10.06 (5.89) |
-41.45% | Details | |
| 5/5/2026 | Aclaris Therapeutis | ACRS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/27/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 4/24/2026 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/20/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2026 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2026 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2026 | Regeneron Pharma | REGN | New Coverage | Overweight (N/A) |
737.71 (654.27) |
-11.31% | Details | |
| 3/24/2026 | LENZ Therapeutics Inc | LENZ | Maintain | Overweight (N/A) |
|
Details | ||
| 3/24/2026 | Context Therapeutics | CNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2026 | Kalaris | KLRS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/13/2026 | Allogene | ALLO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2026 | Kymera Therapeutics | KYMR | New Coverage | Overweight (N/A) |
91.01 (113.51) |
24.72% | Details | |
| 2/23/2026 | Arcellx Inc. | ACLX | Downgrade | Neutral (Overweight) |
64.11 (115.07) |
79.49% | Details | |
| 2/20/2026 | OKYO Pharma Ltd. | OKYO | New Coverage | Overweight (N/A) |
1.76 (1.57) |
-10.8% | Details | |
| 2/19/2026 | Perspective Therapeutics Inc | CATX | New Coverage | Overweight (N/A) |
5.03 (3.63) |
-27.83% | Details | |
| 1/29/2026 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2026 | Crescent Biopharma Inc | CBIO | New Coverage | Overweight (N/A) |
11.75 (17.09) |
45.45% | Details | |
| 1/16/2026 | Centessa Pharmaceuticals | CNTA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/25/2025 | Opus Genetics | IRD | New Coverage | Overweight (N/A) |
1.91 (4.23) |
121.47% | Details | |
| 11/5/2025 | Ascentage Pharma Group | AAPG | New Coverage | Overweight (N/A) |
34.30 (18.50) |
-46.06% | Details | |
| 10/30/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/30/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/30/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2025 | Corbus Pharmaceuticals | CRBP | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2025 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2025 | LENZ Therapeutics Inc | LENZ | Maintain | Overweight (N/A) |
|
Details | ||
| 10/3/2025 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2025 | Monopar Therapeutics | MNPR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2025 | Compass Therapeutics | CMPX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2025 | Viking Therapeutic | VKTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2025 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Overweight (N/A) |
0.00 (8.11) |
0% | Details | |
| 7/29/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 7/23/2025 | Kalaris | KLRS | New Coverage | Neutral (N/A) |
2.42 (4.75) |
96.28% | Details | |
| 7/22/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 7/21/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 7/17/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 7/10/2025 | Aclaris Therapeutis | ACRS | New Coverage | Overweight (N/A) |
1.45 (5.56) |
283.45% | Details | |
| 7/8/2025 | Arcellx Inc. | ACLX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/26/2025 | Context Therapeutics | CNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 6/16/2025 | Sarepta Therapeutics | SRPT | Downgrade | Neutral (Overweight) |
37.31 (19.28) |
-48.32% | Details | |
| 6/6/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/20/2025 | Centessa Pharmaceuticals | CNTA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2025 | Solid Biosciences | SLDB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2025 | Allogene | ALLO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2025 | Taysha Gene Therapies | TSHA | New Coverage | Overweight (N/A) |
1.82 (6.53) |
258.79% | Details | |
| 4/21/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2025 | Centessa Pharmaceuticals | CNTA | New Coverage | Overweight (N/A) |
14.51 (40.50) |
179.12% | Details | |
| 3/21/2025 | Elevation Oncology | ELEV | Downgrade | Neutral (Overweight) |
0.48 (0.37) |
-22.92% | Details | |
| 3/19/2025 | Monopar Therapeutics | MNPR | New Coverage | Overweight (N/A) |
34.23 (97.79) |
185.69% | Details | |
| 2/19/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/19/2025 | Compass Therapeutics | CMPX | New Coverage | Overweight (N/A) |
3.38 (2.27) |
-32.84% | Details | |
| 2/12/2025 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/6/2025 | Viking Therapeutic | VKTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/29/2025 | Cargo Therapeutics | CRGX | Downgrade | Neutral (Overweight) |
13.65 (4.47) |
-67.25% | Details | |
| 1/14/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/18/2024 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/2/2024 | Viking Therapeutic | VKTX | New Coverage | Overweight (N/A) |
54.51 (37.44) |
-31.32% | Details | |
| 12/2/2024 | Corbus Pharmaceuticals | CRBP | New Coverage | Overweight (N/A) |
17.64 (9.25) |
-47.56% | Details | |
| 11/27/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/25/2024 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2024 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/19/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2024 | Immunome Inc. | IMNM | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2024 | Allogene | ALLO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2024 | Arcellx Inc. | ACLX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2024 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/6/2024 | Arcellx Inc. | ACLX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2024 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/19/2024 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 9/12/2024 | Cargo Therapeutics | CRGX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/11/2024 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/4/2024 | BridgeBio Pharma | BBIO | New Coverage | Overweight (N/A) |
28.74 (77.19) |
168.58% | Details | |
| 8/13/2024 | Cargo Therapeutics | CRGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | Immunome Inc. | IMNM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/17/2024 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/16/2024 | Allogene | ALLO | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2024 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/1/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/28/2024 | Elevation Oncology | ELEV | Maintain | Overweight (N/A) |
|
Details | ||
| 6/27/2024 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 6/27/2024 | Cargo Therapeutics | CRGX | New Coverage | Overweight (N/A) |
14.90 (13.65) |
-8.39% | Details | |
| 6/26/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2024 | Allogene | ALLO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/13/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/3/2024 | Elevation Oncology | ELEV | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2024 | Sarepta Therapeutics | SRPT | New Coverage | Overweight (N/A) |
116.25 (37.31) |
-67.91% | Details | |
| 5/31/2024 | Solid Biosciences | SLDB | New Coverage | Overweight (N/A) |
7.56 (10.84) |
43.39% | Details | |
| 5/31/2024 | Ocular Therapeutix | OCUL | New Coverage | Overweight (N/A) |
5.87 (9.64) |
64.22% | Details | |
| 5/31/2024 | Immunome Inc. | IMNM | New Coverage | Overweight (N/A) |
14.62 (23.61) |
61.49% | Details | |
| 5/31/2024 | Elevation Oncology | ELEV | New Coverage | Overweight (N/A) |
3.97 (0.48) |
-87.91% | Details | |
| 5/31/2024 | Apellis Pharmaceuticals | APLS | New Coverage | Neutral (N/A) |
41.11 (41.03) |
-0.19% | Details | |
| 5/31/2024 | Allogene | ALLO | New Coverage | Overweight (N/A) |
2.33 (2.08) |
-10.73% | Details | |
| 5/31/2024 | Arcellx Inc. | ACLX | New Coverage | Overweight (N/A) |
50.45 (64.11) |
27.08% | Details |
